A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC.
CNN
EGFR
KRAS
NSCLC
ensembles
machine learning
radiogenomics
Journal
Tomography (Ann Arbor, Mich.)
ISSN: 2379-139X
Titre abrégé: Tomography
Pays: Switzerland
ID NLM: 101671170
Informations de publication
Date de publication:
29 04 2021
29 04 2021
Historique:
received:
06
04
2021
revised:
23
04
2021
accepted:
27
04
2021
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
3
8
2021
Statut:
epublish
Résumé
Lung cancer causes more deaths globally than any other type of cancer. To determine the best treatment, detecting EGFR and KRAS mutations is of interest. However, non-invasive ways to obtain this information are not available. Furthermore, many times there is a lack of big enough relevant public datasets, so the performance of single classifiers is not outstanding. In this paper, an ensemble approach is applied to increase the performance of EGFR and KRAS mutation prediction using a small dataset. A new voting scheme, Selective Class Average Voting (SCAV), is proposed and its performance is assessed both for machine learning models and CNNs. For the EGFR mutation, in the machine learning approach, there was an increase in the sensitivity from 0.66 to 0.75, and an increase in AUC from 0.68 to 0.70. With the deep learning approach, an AUC of 0.846 was obtained, and with SCAV, the accuracy of the model was increased from 0.80 to 0.857. For the KRAS mutation, both in the machine learning models (0.65 to 0.71 AUC) and the deep learning models (0.739 to 0.778 AUC), a significant increase in performance was found. The results obtained in this work show how to effectively learn from small image datasets to predict EGFR and KRAS mutations, and that using ensembles with SCAV increases the performance of machine learning classifiers and CNNs. The results provide confidence that as large datasets become available, tools to augment clinical capabilities can be fielded.
Identifiants
pubmed: 33946756
pii: tomography7020014
doi: 10.3390/tomography7020014
pmc: PMC8162978
doi:
Substances chimiques
KRAS protein, human
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
154-168Subventions
Organisme : NCI NIH HHS
ID : U01 CA143062
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA200464
Pays : United States
Références
Exp Ther Med. 2015 Jun;9(6):2095-2103
pubmed: 26136941
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
Sci Rep. 2020 Feb 27;10(1):3625
pubmed: 32107398
Comb Chem High Throughput Screen. 2009 Nov;12(9):908-16
pubmed: 19531006
Ann Nucl Med. 2020 Jan;34(1):49-57
pubmed: 31659591
J Mol Diagn. 2008 Nov;10(6):493-5
pubmed: 18832458
Front Oncol. 2020 Oct 26;10:578756
pubmed: 33194700
Eur J Radiol. 2009 May;70(2):232-41
pubmed: 19303233
Transl Oncol. 2021 Jan;14(1):100954
pubmed: 33232920
IEEE/ACM Trans Comput Biol Bioinform. 2019 Nov-Dec;16(6):1794-1801
pubmed: 29993750
Sci Rep. 2017 Jan 31;7:41674
pubmed: 28139704
J Thorac Dis. 2010 Mar;2(1):48-51
pubmed: 22263017
Future Oncol. 2015;11(11):1611-23
pubmed: 26043215
Proc Int Jt Conf Neural Netw. 2018 Jul;2018:
pubmed: 30443438
Eur Respir J. 2019 Mar 28;53(3):
pubmed: 30635290
Transl Oncol. 2014 Feb 01;7(1):72-87
pubmed: 24772210
Sci Data. 2018 Oct 16;5:180202
pubmed: 30325352
Ther Adv Med Oncol. 2011 May;3(3):113-25
pubmed: 21904575
Clin Lung Cancer. 2016 Sep;17(5):441-448.e6
pubmed: 27017476
Cancer Imaging. 2018 Dec 14;18(1):52
pubmed: 30547844